The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | Longer-term follow-up in CAR-T trials
David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses that we are now getting a longer-term follow-up in key CAR-T trials for Lymphoma. Namely, the JULIET (NCT02445248) and ZUMA-1 (NCT02348216) trial. Prof. Maloney mentions ongoing trials working to treat patients at an earlier disease state and in other histologies. Lisocabtagene maraleucel is being targeted in chronic lymphocytic leukemia (CLL). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2018, held in Amsterdam, Netherlands.
